Clinical Trial Update: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and efficacy of switching virologically suppressed HIV-1-infected participants to a doravirine/tenofovir/lamivudine regimen; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine (doravirine)
• Lamivudine (lamivudine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-04-03